Lineage Cell Therapeutics (LCTX) closed at $1.00 on October 30, 2026, down 2.9% from the previous close, on volume of 1,099,080 shares (30-day average 1,538,773).
Data as of October 30, 2026.
30-Oct-2026
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha News (Thu, 29-Oct 3:44 PM ET)
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Lineage Therap (LCTX)
TipRanks (Thu, 29-Oct 10:50 AM ET)
Lineage Provides Update on ReSonance Program for Hearing Loss
Business Wire (Thu, 29-Oct 8:00 AM ET)
Business Wire (Tue, 8-Sep 8:00 AM ET)
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire (Thu, 6-Aug 4:01 PM ET)
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Lineage Cell Therapeutics trades on the AMEX stock market under the symbol LCTX.
As of October 30, 2026, LCTX stock price declined to $1.00 with 1,099,080 million shares trading.
LCTX has a beta of 1.65, meaning it tends to be more sensitive to market movements. LCTX has a correlation of 0.16 to the broad based SPY ETF.
LCTX has a market cap of $252.91 million. This is considered a Small Cap stock.
Last quarter Lineage Cell Therapeutics reported $1 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.01.
In the last 3 years, LCTX traded as high as $2.09 and as low as $.37.
The top ETF exchange traded funds that LCTX belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
LCTX has underperformed the market in the last year with a return of -45.7%, while the SPY ETF gained +12.3%. In the last 3 month period, LCTX fell short of the market, returning -9.9%, while SPY returned +2.1%. However, in the most recent 2 weeks LCTX has outperformed the stock market by returning +2.2%, while SPY returned -1.0%.
LCTX support price is $.99 and resistance is $1.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LCTX shares will trade within this expected range on the day.
